Nicotine as a gateway drug: Biological mechanism in mice identified
- Date:
- November 3, 2011
- Source:
- NIH/National Institute on Drug Abuse
- Summary:
- A landmark study in mice identifies a biological mechanism that could help explain how tobacco products could act as gateway drugs, increasing a person's future likelihood of abusing cocaine and perhaps other drugs as well, according to researchers. The study is the first to show that nicotine might prime the brain to enhance the behavioral effects of cocaine.
- Share:
A landmark study in mice identifies a biological mechanism that could help explain how tobacco products could act as gateway drugs, increasing a person's future likelihood of abusing cocaine and perhaps other drugs as well, according to the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. The study is the first to show that nicotine might prime the brain to enhance the behavioral effects of cocaine.
The gateway drug model is based upon epidemiological evidence that most illicit drug users report use of tobacco products or alcohol prior to illicit drug use. This model has generated significant controversy over the years, mostly relating to whether prior drug exposure (to nicotine, alcohol or marijuana) is causally related to later drug use. Before now, studies have not been able to show a biological mechanism by which nicotine exposure could increase vulnerability to illicit drug use.
In the current study, by researchers at Columbia University, New York City, and published in Science Translational Medicine, mice exposed to nicotine in their drinking water for at least seven days showed an increased response to cocaine. This priming effect depended on a previously unrecognized effect of nicotine on gene expression, in which nicotine changes the structure of the tightly packaged DNA molecule, reprograms the expression pattern of specific genes, in particular the FosB gene that has been related to addiction, and ultimately alters the behavioral response to cocaine.
To examine whether the results from this study paralleled findings in humans, the researchers reexamined statistics from the 2003 National Epidemiological Study of Alcohol Related Consequences to explore the relationship between onset of nicotine use and degree of cocaine dependence. They found that the rate of cocaine dependence was higher among cocaine users who smoked prior to starting cocaine compared to those who tried cocaine prior to smoking.
These findings in mice suggest that if nicotine has similar effects in humans, effective smoking prevention efforts would not only prevent the negative health consequences associated with smoking but could also decrease the risk of progression and addiction to cocaine and possibly other illicit drug use. In the meantime, this mouse model provides a new mechanism to study the gateway theory from a biological perspective.
"Now that we have a mouse model of the actions of nicotine as a gateway drug this will allow us to explore the molecular mechanisms by which alcohol and marijuana might act as gateway drugs," said Eric Kandel, M.D., of Columbia University Medical Center and a senior author of the study. "In particular, we would be interested in knowing if there is a single, common mechanism for all gateway drugs or if each drug utilizes a distinct mechanism."
For more information on nicotine and cocaine, go to www.drugabuse.gov/drugpages/nicotine.html and www.drugabuse.gov/drugpages/cocaine.html.
Story Source:
Materials provided by NIH/National Institute on Drug Abuse. Note: Content may be edited for style and length.
Journal References:
- Amir Levine, Yanyou Huang, Bettina Drisaldi, Edmund A. Griffin, Jr., Daniela D. Pollak, Shiqin Xu, Deqi Yin, Christine Schaffran, Denise B. Kandel, Eric R. Kandel. Molecular Mechanism for a Gateway Drug: Epigenetic Changes Initiated by Nicotine Prime Gene Expression by Cocaine. Science Translational Medicine, 2011; 3 (107): 107ra109 DOI: 10.1126/scitranslmed.3003062
- Nora D. Volkow. Epigenetics of Nicotine: Another Nail in the Coughing. Science Translational Medicine, 2011; 3 (107): 107ps43 DOI: 10.1126/scitranslmed.3003278
Cite This Page: